Menu Menu


GLAXF Financials       Clear


GLAXF        0001131399    
Filing Date Form Type Description Document
2026-05-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-05-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-05-18 6-K TRANSACTION IN OWN SHARES View Document
2026-05-18 6-K JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR View Document
2026-05-14 13F-HR View Document
2026-05-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-05-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-05-11 6-K COLLABORATION WITH CTTQ FOR BEPIROVIRSEN View Document
2026-05-11 6-K GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME View Document
2026-05-06 6-K RESULT OF AGM View Document
2026-05-06 SCHEDULE 13G View Document
2026-05-05 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-05-01 6-K TOTAL VOTING RIGHTS View Document
2026-05-01 6-K HOLDING(S) IN COMPANY View Document
2026-04-29 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-29 6-K 1ST QUARTER RESULTS View Document
2026-04-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-28 6-K BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCE View Document
2026-04-27 6-K EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONS View Document
2026-04-27 6-K TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION View Document
2026-04-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-23 6-K TRANSACTION IN OWN SHARES View Document
2026-04-22 6-K TRANSACTION IN OWN SHARES View Document
2026-04-21 6-K TRANSACTION IN OWN SHARES View Document
2026-04-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-20 6-K BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA View Document
2026-04-20 6-K TRANSACTION IN OWN SHARES View Document
2026-04-17 6-K TRANSACTION IN OWN SHARES View Document
2026-04-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-16 6-K TRANSACTION IN OWN SHARES View Document
2026-04-15 6-K GSK COMPLETES ACQUISITION OF 35PHARMA INC. View Document
2026-04-15 6-K TRANSACTION IN OWN SHARES View Document
2026-04-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-14 6-K TRANSACTION IN OWN SHARES View Document
2026-04-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-13 6-K GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADC View Document
2026-04-13 6-K TRANSACTION IN OWN SHARES View Document
2026-04-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-10 6-K TRANSACTION IN OWN SHARES View Document
2026-04-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-09 6-K TRANSACTION IN OWN SHARES View Document
2026-04-08 6-K EXDENSUR APPROVED FOR CRSWNP IN CHINA View Document
2026-04-08 6-K TRANSACTION IN OWN SHARES View Document
2026-04-07 6-K TRANSACTION IN OWN SHARES View Document
2026-04-02 6-K TRANSACTION IN OWN SHARES View Document
2026-04-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-04-01 6-K TOTAL VOTING RIGHTS View Document
2026-04-01 6-K TRANSACTION IN OWN SHARES View Document
2026-04-01 6-K VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING View Document
2026-03-31 6-K TRANSACTION IN OWN SHARES View Document
2026-03-30 6-K BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA View Document
2026-03-30 6-K EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA View Document
2026-03-30 6-K TRANSACTION IN OWN SHARES View Document
2026-03-27 6-K TRANSACTION IN OWN SHARES View Document
2026-03-27 6-K BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA View Document
2026-03-26 6-K TRANSACTION IN OWN SHARES View Document
2026-03-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-25 6-K NOTICE OF AGM View Document
2026-03-25 6-K TRANSACTION IN OWN SHARES View Document
2026-03-24 6-K TRANSACTION IN OWN SHARES View Document
2026-03-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-23 6-K ADMISSION TO TRADING View Document
2026-03-23 6-K GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS View Document
2026-03-23 6-K TRANSACTION IN OWN SHARES View Document
2026-03-20 6-K TRANSACTION IN OWN SHARES View Document
2026-03-19 6-K LYNAVOY (LINERIXIBAT) APPROVED BY US FDA View Document
2026-03-19 6-K TRANSACTION IN OWN SHARES View Document
2026-03-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-18 6-K TRANSACTION IN OWN SHARES View Document
2026-03-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-17 6-K TRANSACTION IN OWN SHARES View Document
2026-03-16 6-K TRANSACTION IN OWN SHARES View Document
2026-03-13 6-K US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR View Document
2026-03-13 6-K TRANSACTION IN OWN SHARES View Document
2026-03-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-12 6-K TRANSACTION IN OWN SHARES View Document
2026-03-11 6-K TRANSACTION IN OWN SHARES View Document
2026-03-10 6-K TRANSACTION IN OWN SHARES View Document
2026-03-09 6-K BOARD COMMITTEE CHANGE View Document
2026-03-09 6-K GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS View Document
2026-03-09 6-K TRANSACTION IN OWN SHARES View Document
2026-03-06 6-K FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F View Document
2026-03-06 IRANNOTICE IRANNOTICE View Document
2026-03-06 20-F 20-F View Document
2026-03-06 6-K TRANSACTION IN OWN SHARES View Document
2026-03-05 6-K GSK PUBLISHES ANNUAL REPORT 2025 View Document
2026-03-05 6-K TRANSACTION IN OWN SHARES View Document
2026-03-04 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-04 6-K TRANSACTION IN OWN SHARES View Document
2026-03-03 6-K GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS View Document
2026-03-03 6-K TRANSACTION IN OWN SHARES View Document
2026-03-03 SC TO-T/A SC TO-T/A View Document
2026-03-02 6-K TRANSACTION IN OWN SHARES View Document
2026-03-02 6-K TOTAL VOTING RIGHTS View Document
2026-02-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-27 6-K TRANSACTION IN OWN SHARES View Document
2026-02-26 6-K LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA View Document
2026-02-26 6-K BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW View Document
2026-02-26 6-K TRANSACTION IN OWN SHARES View Document
2026-02-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299